# Burrage Capital Management LLC

> Institutional holdings reported to the SEC as of Q2 2021 on Form 13F. CIK 1796461. Source: https://holderbook.com/funds/1796461-burrage-capital-management-llc/

- Reported value: $99.7M
- Positions: 22
- Weight of the ten largest: 70.7%
- Filed: 2021-08-16

A 13F reports long US equity positions only. Short positions, bonds, foreign listings, private holdings and cash are not visible, so this is not the manager's whole book.

## Holdings

| Security | Ticker | Value | Shares | Weight | Quarters held |
|---|---|---|---|---|---|
| BIOCRYST PHARMACEUTICALS INC | [BCRX](https://holderbook.com/stocks/BCRX/) | $13.7M | 864,916 | 13.7% | 3 |
| INTELLIA THERAPEUTICS INC | [NTLA](https://holderbook.com/stocks/NTLA/) | $10.3M | 63,634 | 10.3% | 3 |
| EPIZYME INC | [EPZM](https://holderbook.com/stocks/EPZM/) | $7.0M | 836,802 | 7.0% | 7 |
| ESSA PHARMA INC | [EPIX](https://holderbook.com/stocks/EPIX/) | $6.8M | 237,442 | 6.8% | 2 |
| NEOGENOMICS INC | [NEO](https://holderbook.com/stocks/NEO/) | $6.7M | 147,921 | 6.7% | 7 |
| MEI PHARMA INC | [MEIPXXXX](https://holderbook.com/stocks/MEIPXXXX/) | $6.6M | 2,331,313 | 6.7% | 7 |
| CRINETICS PHARMACEUTICALS IN | [CRNX](https://holderbook.com/stocks/CRNX/) | $5.6M | 294,620 | 5.6% | 7 |
| CYTOKINETICS INC | [CYTK](https://holderbook.com/stocks/CYTK/) | $4.8M | 244,673 | 4.9% | 6 |
| AMICUS THERAPEUTICS INC | [FOLD](https://holderbook.com/stocks/FOLD/) | $4.8M | 500,000 | 4.8% | 1 |
| HARMONY BIOSCIENCES HLDGS IN | [HRMY](https://holderbook.com/stocks/HRMY/) | $4.2M | 150,000 | 4.2% | 2 |
| INOZYME PHARMA INC | [INZY](https://holderbook.com/stocks/INZY/) | $4.1M | 242,517 | 4.1% | 3 |
| Y-MABS THERAPEUTICS INC | [YMAB](https://holderbook.com/stocks/YMAB/) | $3.9M | 114,454 | 3.9% | 7 |
| MIRUM PHARMACEUTICALS INC | [MIRM](https://holderbook.com/stocks/MIRM/) | $3.6M | 205,866 | 3.6% | 3 |
| ADC THERAPEUTICS SA | [ADCT](https://holderbook.com/stocks/ADCT/) | $3.0M | 124,875 | 3.0% | 5 |
| VERASTEM INC | [VSTMXXXX](https://holderbook.com/stocks/VSTMXXXX/) | $2.9M | 705,585 | 2.9% | 1 |
| MERUS N V | [MRUS](https://holderbook.com/stocks/MRUS/) | $2.8M | 130,683 | 2.8% | 5 |
| GERON CORP | [GERN](https://holderbook.com/stocks/GERN/) | $2.7M | 1,912,673 | 2.7% | 2 |
| AVROBIO INC | [AVRO](https://holderbook.com/stocks/AVRO/) | $2.2M | 244,920 | 2.2% | 3 |
| REVOLUTION MEDICINES INC | [RVMD](https://holderbook.com/stocks/RVMD/) | $1.6M | 50,000 | 1.6% | 1 |
| BLACK DIAMOND THERAPEUTICS I | [BDTX](https://holderbook.com/stocks/BDTX/) | $1.3M | 110,447 | 1.3% | 3 |
| G1 THERAPEUTICS INC | [GTHX](https://holderbook.com/stocks/GTHX/) | $1.0M | 47,708 | 1.0% | 7 |
| TURNING POINT THERAPEUTICS I | [TPTX](https://holderbook.com/stocks/TPTX/) | $169.0K | 2,164 | 0.2% | 6 |

## What the disclosed book did

Not the fund's return. This is the change in value of the positions disclosed on Form 13F, had they been left untouched, against SPY over the same quarter ends.

| Quarter | Book | Market | Difference | Priced |
|---|---|---|---|---|
| Q2 2021 | -3.5% | +8.0% | -11.5% | 99% |
| Q1 2021 | -3.7% | +6.0% | -9.7% | 100% |
| Q4 2020 | +14.9% | +11.6% | +3.2% | 91% |
| Q3 2020 | -11.7% | +8.6% | -20.3% | 100% |
| Q2 2020 | +35.8% | +19.6% | +16.1% | 104% |
| Q1 2020 | -30.4% | -19.9% | -10.5% | 92% |

## Quarter by quarter

| Quarter | Value | Positions |
|---|---|---|
| Q2 2021 | $99.7M | 22 |
| Q1 2021 | $123.4M | 27 |
| Q4 2020 | $131.2M | 25 |
| Q3 2020 | $126.7M | 27 |
| Q2 2020 | $142.9M | 26 |
| Q1 2020 | $101.6M | 31 |
| Q4 2019 | $149.2M | 29 |